Clinical Outcome of Antiviral Therapy on COVID-19 Patients

Gestina Aliska; Andani Eka Putra; Ricvan Dana Nindrea; Widy Nur Utami; SM Rezvi

doi:10.3889/oamjms.2022.8334

Authors

Gestina Aliska Department of Clinical Pharmacology, Dr. M Djamil General Hospital, West Sumatra, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Andalas, West Sumatra, Indonesia
Andani Eka Putra Department of Microbiology, Faculty of Medicine, Universitas Andalas, West Sumatra, Indonesia
Ricvan Dana Nindrea Department of Education and Research, Dr. M Djamil General Hospital, Padang, Indonesia
Widy Nur Utami Pharmacy and Therapeutics Committee, Dr. M Djamil General Hospital, West Sumatra, Indonesia https://orcid.org/0000-0002-3057-8976
SM Rezvi Magister of Biomedical Programme, Faculty of Medicine, Universitas Andalas, West Sumatra, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.8334

Keywords:

Antiviral, Remdesivir, Favipiravir, SARS-Cov-2, COVID-19

Abstract

BACKGROUND: A novel coronavirus-caused pneumonia has been widespread worldwide since the end of 2019. The rapid widespread has prompted the repurposing of drugs based on promising in vitro and therapeutic results with other human coronavirus diseases. These repurposed drugs have mainly included remdesivir, favipiravir, lopinavirritonavir, ribavirin, interferons, and hydroxychloroquine.

AIM: This study aims to evaluate the efficacy of any antiviral for 2019-nCoV infection in a national referral hospital.

METHODS: This research was a retrospective study to evaluate all antiviral clinical responses used in a national referral hospital.

RESULTS: Based on gender, there is a similar frequency from all patients. Hematology, followed by cardiovascular and pulmonary disease, is the most frequent comorbidity. There is no significant difference between the two groups antiviral treatment for a length of stay parameter. The most extended length of stay is 29 days. About 64.5% of patients are cured of SARS-Cov-2 infection. In the remdesivir group, we find that the mortality is significantly high.

CONCLUSION: The clinical outcome of these antiviral treatments is similar, except for mortality. The severity of COVID-19 causes differences in mortality.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507-13. https://doi.org/10.1016/ S0140-6736(20)30211-7 PMid:32007143 DOI: https://doi.org/10.1016/S0140-6736(20)30211-7

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Geneva: World Health Organization; 2021. Available from: https://covid19.who.int [Last accessed on 2021 Feb 24].

Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The rationale for potential pharmacotherapy of COVID-19. Pharmaceuticals (Basel). 2020;13(5):96. https://doi.org/10.3390/ph13050096 PMid:32423024 DOI: https://doi.org/10.3390/ph13050096

Shi X, Lu Y, Li R, Tang Y, Shi N, Song F, et al. Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, China. J Med Virol. 2020;92(10):1922-31. https://doi.org/10.1002/jmv.25893 PMid:32297985 DOI: https://doi.org/10.1002/jmv.25893

Martinez MA. Clinical trials of repurposed antivirals for SARS-CoV-2. Antimicrob Agents Chemother. 2020;64(9):01101-20. https://doi.org/10.1128/AAC.01101-20 PMid:32631826 DOI: https://doi.org/10.1128/AAC.01101-20

WHO Solidarity Trial Consortium, Pan H, Peto R, Henao- Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for Covid-19-Interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497-511. https://doi.org/10.1056/NEJMoa2023184 PMid:33264556 DOI: https://doi.org/10.1056/NEJMoa2023184

Piscoya A, Ng-Sueng LF, Del Riego AP, Cerna-Viacava R, Pasupuleti V, Roman YM, et al. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. PLoS One. 2020;15(12):0243705. https://doi.org/10.1371/journal.pone.0243705 PMid:33301514 DOI: https://doi.org/10.1371/journal.pone.0243705

Shenoy S. SARS-CoV-2 (COVID-19), viral load and clinical outcomes; Lessons learned one year into the pandemic: A systematic review. World J Crit Care Med. 2021;10(4):132-50. https://doi.org/10.5492/wjccm.v10.i4.132 PMid:34316448 DOI: https://doi.org/10.5492/wjccm.v10.i4.132

Jen HH, Chang WJ, Lin TY, Hsu CY, Yen MF, Lai CC, et al. Evaluating clinical efficacy of antiviral therapy for COVID-19: A surrogate endpoint approach. Infect Dis Ther. 2021;10(2):815-25. https://doi.org/10.1007/s40121-021-00431-9 PMid:33738764 DOI: https://doi.org/10.1007/s40121-021-00431-9

Liao SH, Hung CC, Chen CN, Yen JY, Hsu CY, Yen AM, et al. Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis. J Formos Med Assoc. 2021;120(Suppl 1):77-85. https://doi.org/10.1016/j.jfma.2021.04.026 PMid:34074579 DOI: https://doi.org/10.1016/j.jfma.2021.04.026

Garibaldi BT, Wang K, Robinson ML, Zeger SL, Bandeen-Roche K, Wang MC, et al. Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19. JAMA Netw Open. 2021;4(3):213071. https://doi.org/10.1001/jamanetworkopen.2021.3071 PMid:33760094 DOI: https://doi.org/10.1001/jamanetworkopen.2021.3071

Butt AG, Ahmed J, Shah SM, Capriles CA, Al-Rihani H, Ahmed B, et al. Evaluating the clinical outcomes of remdesivir among patients admitted with COVID-19 in a tertiary care hospital. Cureus. 2021;13(11):19487. https://doi.org/10.7759/cureus.19487 PMid:34912628 DOI: https://doi.org/10.7759/cureus.19487